National Health (August 2026 First New Brand Statutory Price Reduction) (Exercise of Ministerial discretion) Determination 2026

Overview

The National Health (August 2026 First New Brand Statutory Price Reduction) (Exercise of Ministerial discretion) Determination 2026, also known as PB 84 of 2026, was enacted to address the need for statutory price reductions on specific brands of pharmaceutical items. This determination was made under the authority of sections 99ACB of the National Health Act 1953 by Soumya Sudarshan, Acting Assistant Secretary of the PBS Listing, Pricing and Policy Branch, Technology Assessment and Access Division, Department of Health, Disability and Ageing. The primary objective of this legislation is to exercise the Minister's discretion in setting prices for designated pharmaceutical brands to align with the approved ex-manufacturer price, effective from 1 August 2026. This legislative instrument aims to ensure the equitable pricing of pharmaceutical items, facilitating better access to essential medications for consumers.

Scope and Application

The National Health (August 2026 First New Brand Statutory Price Reduction) (Exercise of Ministerial discretion) Determination 2026 applies to specified brands of pharmaceutical items listed in Schedule 1 of the instrument. These pharmaceutical items, which are not combination items, are subject to a price reduction as determined under sections 99ACB of the National Health Act 1953. The instrument identifies the agreed price of particular brands of pharmaceutical items, ensuring that their prices are aligned with the approved ex-manufacturer price as of the day before the determination day. This legislative instrument is applicable across Australia and is enforced through the National Health Act 1953. Notably, the instrument excludes any combination pharmaceutical items from the scope of the price reduction, focusing solely on individual brands as specified in the Schedule. The instrument is effective from 1 August 2026 and is made by the Acting Assistant Secretary of the Department of Health, Disability and Ageing, who is a delegate of the Minister for Health and Ageing.

Key Provisions

The National Health (August 2026 First New Brand Statutory Price Reduction) (Exercise of Ministerial discretion) Determination 2026 (sections 1-5) establishes the terms under which certain pharmaceutical items will undergo a statutory price reduction effective from 1 August 2026. This determination, made under sections 99ACB of the National Health Act 1953, mandates that specific brands of pharmaceutical items listed in Schedule 1 will have their agreed prices adjusted to align with the approved ex-manufacturer price as of the day before the determination date. These pharmaceutical items, which include drugs such as Progesterone in capsule form, are subject to this price adjustment to streamline costs and ensure equitable pricing within the health sector. Entities and parties governed by this determination, primarily pharmaceutical manufacturers and suppliers, must ensure compliance with the specified price reductions for the listed pharmaceutical items. This includes accurately calculating and implementing the new agreed prices as stipulated in the determination, thereby maintaining transparency and fairness in the pricing of these essential health products. Manufacturers and suppliers are required to update their pricing structures accordingly to reflect these statutory reductions, ensuring that the changes are communicated effectively to all stakeholders within the supply chain. Failure to comply with the provisions outlined in the determination may result in various consequences. While the specific penalties for non-compliance are not detailed within the determination, breaches of similar statutory requirements under the National Health Act 1953 can lead to substantial penalties. For instance, under section 99A of the Act, penalties may include fines up to $50,000 for individuals and significantly higher amounts for corporations, alongside potential civil actions and criminal prosecutions. These penalties underscore the importance of adherence to the statutory requirements set forth in the determination to avoid legal repercussions and maintain the integrity of the health sector's pricing mechanisms.